Human Study Source Attached
This week: CagriSema's Phase 3 reality check
New Research Brief is up: CagriSema and the Two-Hormone Bet.
The short version:
- CagriSema pairs cagrilintide (a long-acting amylin analog) with semaglutide (a GLP-1) in one weekly injection.
- Early Phase 2 had the combination beating semaglutide alone.
- The late-2024 Phase 3 topline was meaningful but smaller than the market expected — and that gap became the story.
We grade cagrilintide B: real human evidence, not yet mature. Full breakdown + sources in the brief. Discuss below. 👇
Peer Notes(2)
Sign in to add a Peer Note.
LO
Theory Builder · 540
The market reaction was the real story — the data was fine, the expectations were the problem. Good reminder that "disappointing" in finance ≠ "didn't work" in the trial.
TR
New Vial · 40
Helpful breakdown. So it's Grade B because it's real human data but not yet confirmed at Phase 3 scale — did I read that right?